Plainsboro, New Jersey, April 29, 2003-- Integra LifeSciences Holdings Corporation (Nasdaq: IART) today announced that members of the Department of Neurosurgery and Surgery of the University of Pennsylvania will present the results of three clinical studies that assessed the clinical utility of monitoring oxygen in head trauma cases at the 2003 American Association of Neurological Surgeons Convention in San Diego. Among other things, the studies considered the application of Integra's LICOXÒ Brain Tissue Oxygen Monitoring system to the management of brain injuries, including patients with severe traumatic brain injury or subarachnoid hemorrhage.

The key findings of these studies include the following:
• Patient management directed at maintaining cerebral brain tissue oxygenation in the presence of intractable intracranial hypertension is associated with improved outcome.
• The treatment of refractory intracranial hypertension with Decompressive Hemicraniectomy (DCH) has been shown to result in improved cerebral oxygenation.
• Re-establishing normal hematocrit by packed red blood cell transfusion is associated with an increase in local brain oxygenation.
• Physiologic manipulations in the intensive care unit frequently affect brain oxygen levels.

"In addition to achieving our clinical objectives, the studies also showed that the LICOX Brain Tissue Oxygen Monitoring System is a useful addition to existing neuromonitoring methods," said, Peter D. LeRoux M.D., FACS, Associate Professor and Vice Chairman, Department of Neurosurgery, University of Pennsylvania. "Cerebral hypoxia in traumatic brain injury and subarachnoid hemorrhage patients is frequently observed and is closely associated with neurological outcome. However, it has been demonstrated that episodes of cerebral hypoxia may occur when the patient is in the normal range for intracranial pressure and cerebral perfusion pressure. Monitoring brain oxygen levels with LICOX® is a reliable method, with no artifacts or complications, which can improve the outcome of severely brain injured patients.

The LICOX system is sold through the Integra NeuroSciencesT sales organization. Integra NeuroSciences is a leading provider of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neurotrauma, and related critical care. Integra NeuroSciences' direct selling effort in the United States and Europe currently involves more than 100 professionals. In all other markets, Integra NeuroSciences products are sold through a network of distributors.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neuro-trauma and neurosurgery, plastic and reconstructive surgery, and soft tissue repair. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. The Company has its corporate headquarters in Plainsboro, New Jersey, with manufacturing and research facilities located throughout the world. The Company has approximately 860 permanent employees.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning future alternative clinical uses of the LICOX product. The accuracy of such forward-looking statements is necessarily subject to risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, physicians' willingness to use the LICOX® product may affect the prospects for its use in additional clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2002 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

Source: Integra LifeSciences Holdings Corporation

Contact:
Integra LifeSciences Holdings Corporation
John B. Henneman, III
Executive Vice President
Chief Administrative Officer
(609) 936-2481
jhenneman@integra-ls.com